ArticleBMC nephrology2026
Muscle strength, neuromuscular function, and functional measures across stages of chronic kidney disease.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals with chronic kidney disease (CKD) exhibit impairments to skeletal muscle function when compared to age-matched healthy controls. The current study was designed to compare muscle strength, functional measures, and the levels of some biomarkers across the stages of CKD compared to age-matched healthy controls (HC).
methodsThirty-nine individuals with either CKD stage 3 (n = 10, age = 69.7 ± 9.95), stage 4 (n = 10, age = 66.5 ± 6.95), or stage 5 (n = 9, age = 58.7 ± 13.01) or age-matched HC (n = 10, age = 62.3 ± 10.4) were recruited to participate in this study. After obtaining approval from a physician, participants came to the lab on two occasions. The first lab visit consisted of the completion of an informed consent form, a health screening form, and a medical history questionnaire. Anthropometric measurements were then taken, as well as a blood sample via venipuncture. Next, a familiarization trial with maximum voluntary isometric contractions (MVIC) was performed, in addition to the six-minute walk test (6MWT), and the short physical performance battery test (SPPB). Participants visited the lab for the second time after a minimum of 72 h had passed. During this visit, three MVICs were performed. Force was recorded using a load cell. Concentrations of uremic toxins indoxyl sulfate (IS) and p-cresyl sulfate (pCS), along with inflammatory markers interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-⍺) were analyzed using commercially available enzyme-linked immunosorbent assays per the manufacturer’s instructions.
resultsUremic toxins IS and pCS, as well as the inflammatory marker IL-6 all increased significantly from HC to CKD stage 3, to CKD stage 4, and to CKD stage 5. TNF-⍺ increased significantly from HC to CKD stage 3, but not between the CKD groups. SPPB, MVIC, and 6MWT performance decreased significantly between HC to CKD stage 3, to CKD stage 4. No significant change was found in SPPB, MVIC, and 6MWT from CKD stage 4 to CKD stage 5.
conclusionAs CKD progresses, indices of muscular strength and functional measures decline compared to HC but the biomarkers, uremic toxins and markers of inflammation increase. These changes in biomarkers are associated with worsened skeletal muscle function. ‘. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.